Category: Partners

NEW YORK CITY, NEW YORK / ACCESS Newswire / August 27, 2025 / doola, the AI Business-in-a-Box™ for global e-commerce entrepreneurs, today announced the launch of its AI Co-Founder, the first intelligent business partner that cuts founders’ back-office work from hours per week to minutes. With this launch, e-commerce entrepreneurs can now get from idea to first sale faster and automate the complex operations of scaling a U.S. business.

Solving the $6 Trillion E-Commerce Paradox

Global e-commerce sales are projected to surpass $6 trillion in 2025. While starting a Shopify or Amazon store takes minutes, running one remains a major hurdle. Founders juggle compliance deadlines, tax filings, banking setup, and bookkeeping, often without local expertise. doola’s AI Co-Founder removes that burden by integrating these functions into one intelligent platform that proactively guides each founder’s next step.

What AI Co-Founder Delivers Today

Unlike generic chatbots, AI Co-Founder is built for e-commerce entrepreneurs and automates tasks that usually drain founders’ time:

• Banking & Payments: Helps founders globally set up U.S. accounts and Shopify Payments quickly.

• Compliance & Filings: Tracks state deadlines and fees, sending reminders before obligations are due.

• Bookkeeping & Accounting: Advises on accounting methods and expense categorization to keep your books clean.

• U.S. Tax Guidance: Explains filing requirements based on a founder’s home country and U.S. business structure.

Arjun Mahadevan, CEO and Founder of doola, said: “E-Commerce entrepreneurs don’t want 10 browser tabs and five service providers. They want one trusted partner who gets it done. AI Co-Founder is that partner; never sleeps and is available 24/7, fluent in 175+ countries’ unique challenges, and getting smarter with every interaction. doola is not a formation service; we’re an AI Business-in-a-Box™ for E-Commerce. Our AI Co-Founder is our first step toward an intelligent, agentic, automated back-office that works for you, so you can focus on what you do best while doola handles the rest.”

Tommy Castellano, CEO and Founder of Kyvo, said: “Running an e-commerce brand is a 24/7 job. doola already saves me hours on bookkeeping, but the new AI Co-Founder is a game-changer. Automating compliance, tax prep and having knowledge at my fingertips means I can get back to focusing on my product and customers.”

Jishnu Bhattacharjee, Managing Director at Nexus Venture Partners, said: “doola’s AI Co-Founder redefines what it means to support global entrepreneurs. It’s not just about offering services – it’s about delivering intelligence, personalization, and peace of mind. doola has built the infrastructure layer for global entrepreneurship. Now they’re adding intelligence and agentic automation.”

Arjun Gandhi, Vice President at Nexus Venture Partners, said: “Founders don’t fail for lack of ambition. They fail because no one shows them the path. AI Co-Founder is the missing guidance layer. By embedding context-aware intelligence directly into the founder journey, doola is building a seamless and personalized experience for starting a company.”

About doola

doola (Y Combinator S20) is the AI Business-in-a-Box™ for global e-commerce entrepreneurs. The platform provides an all-in-one back-end solution including U.S. LLC formation, Registered Agent services, an EIN, a U.S. business bank account and payment processor access, bookkeeping, tax filings, and compliance. By integrating these complex services, doola empowers founders from over 175 countries to start and scale their U.S. businesses with confidence. doola is backed by $13 million in venture capital from Y Combinator, Nexus Venture Partners, HubSpot Ventures, and more. Visit www.doola.com.

SOURCE: doola

View the original press release on ACCESS Newswire

HOUSTON, TEXAS / ACCESS Newswire / August 27, 2025 / US Med-Equip (USME), the nation’s top-rated provider of medical equipment rentals and management services, is expanding its operations support across the country with two larger facilities–a national distribution center and a national production center–to meet rising demand from its hospital customers.

The new USME Distribution Center in northwest Houston handles shipping and receiving of critical medical equipment, including infusion pumps, ventilators, patient monitors and specialty beds rented daily by thousands of hospitals. Entrusted for its 2-hour delivery standard, the new facility strengthens USME’s logistics network, helping teams nationwide respond even faster to hospitals’ ever-changing patient care needs.

USME’s new national production center, located alongside the company’s northwest Houston headquarters, serves as one of the hubs for its biomedical operations. There, manufacturer-certified biomedical technicians maintain and service the company’s rental fleet of medical equipment with the industry’s highest standards of safety and performance.

Recognized as an Inc. Power Partner and CIO 100 for helping hospitals optimize resources and patient outcomes, USME also leads the way in specialized equipment for bariatric care, one of the fastest-growing needs in healthcare today.

“As we continue expanding, we’re strengthening every part of our operation to deliver the unmatched service and equipment quality our hospital partners expect,” Greg Salario, CEO of US Med-Equip, said about the company setting the standard for the industry.

Houston-based USME operates from more than 100 locations nationwide and continues to expand as more hospitals turn to its team for medical equipment rental and management services. The Top Workplace is investing in new facilities, technology and clinical support to help more hospitals than ever meet rising patient care demands.

About US Med-Equip:

USME partners with top hospitals to provide the highest quality medical equipment, including monitoring devices, ventilators, infusion pumps, patient beds and more. From on-demand delivery of medical equipment rentals to asset management and onsite biomedical support services, USME is the highest-rated medical equipment partner for hospitals across the country.

Contact Information

Buse Kayar
busek@accessnewswire.com

SOURCE: US Med-Equip

Related Images

View the original press release on ACCESS Newswire

Dr. Nneka J. McGee chose ACE’s low-cost, flexible, online doctoral program for her studies; her doctoral research, which examined how teachers learn about and use artificial intelligence tools, caught the attention of leading institutions and established her as a national leader on the topic of AI in K-12 education.

INDIANAPOLIS, IN / ACCESS Newswire / August 27, 2025 / Accomplished educator Dr. Nneka J. McGee turned her professional research in artificial intelligence into a doctoral degree at American College of Education (ACE), establishing her as a national leader in implementing AI in K-12 classrooms – just as a new presidential executive order calls for more AI education in K-12 schools.

ACE, founded in 2005 and accredited by the Higher Learning Commission, is a national innovator in providing quality, affordable and online graduate degrees, and is the third-highest conferrer of education master’s degrees in the United States.¹

For her doctoral dissertation, McGee conducted original research into K-12 teachers’ experiences learning about AI and attempting to implement it in their classrooms. She completed her program in December 2023 and graduated from ACE in 2024.

She chose to pursue her degree at ACE because of her concerns about the high tuition and student loan debt at most graduate programs. She also wanted the flexibility of online education so she could continue her career – something difficult or impossible if she attended a traditional bricks-and-mortar university.

ACE’s doctoral tuition is under $25,000² and among the lowest in the United States. It has not raised tuition in eight years³ and the college forgoes federal student loan programs, which helps keep costs low. As a result, McGee was able to graduate from ACE without accruing any student loans.

“That was really a determining factor for me, and ACE also has the accreditation that is necessary,” McGee said. “Because of that and the flexibility of the program, I was able to keep working and, during my program, I rose from director to executive director to chief academic officer.”

When McGee began her research, she was working as a director of advanced academics in a Dallas-area school district and building the framework for launching an AI initiative aimed at helping students learn more about the technology. ChatGPT was still years from becoming a household word, and she realized there were few studies on the use of AI in the United States’ K-12 schools.

“I noticed there is this thing, AI, that is going to transform education, and I thought not enough people are talking about it or looking at the implications. That was the genesis for my research,” McGee said.

Through a questionnaire and follow-up interviews, she gathered information from a slate of K-12 teachers nationwide on their efforts to learn about AI educational tools and to bring them into the classroom.

McGee found that teachers were using AI-powered tools to save time on tasks, and that they saw increased student engagement when AI was incorporated into learning environments. However, teachers also faced significant challenges in attaining those outcomes.

“One of the biggest findings is that teachers don’t have enough access to quality professional development in this space,” she said. While AI is a hot topic of discussion, teachers have limited access to people with enough expertise to implement it. Teachers had to seek out the few options for professional development on their own.

She also found that when teachers did find a way to access AI training, they often faced the challenge of having limited time to pursue the professional development side, let alone implement it in their classrooms.

Doctoral students often face similar challenges as they study and write their dissertations. McGee said ACE’s online classes are more effective than traditional on-campus lectures because “you actually have more time to sit and really process the information, because it is flexible, on your own time, when you’re in the best condition to learn.”

ACE uses a chapter-by-chapter dissertation model, where students work on their dissertation progressively throughout their doctoral program, rather than waiting until the end. In addition, dedicated faculty members guide students through each phase of the dissertation, including topic selection, literature review, research methodology, data analysis and the final defense.   

Professors also offered invaluable support when she felt challenged while writing her dissertation. “One of my professors kept checking in on me – he may have noticed it in my emails or responses – and he said, ‘OK, we need to talk like, so call me and let’s talk,’” McGee said. “That call really changed everything. He said, ‘Let’s look at this, how are you feeling, why are you feeling this way?’ And I realized what I needed to do, and that weekend I finished everything up. So it was a pivotal moment.”

The dissertation, now available online, recommends that school districts invest in professional development and resources that promote responsible AI implementation – an idea echoed months later in April’s presidential executive order.

McGee’s work has caught the attention of many organizations developing policies and uses for AI, allowing her to serve as a panelist for the U.S. Department of Education and Carnegie Mellon University. She has also collaborated on projects with Digital Promise and the Stanford Accelerator for Learning at Stanford University. McGee has been in high demand as a keynote or featured speaker on AI in education at multiple conferences.

She credits much of her success to ACE’s program and the quality and personal attention of its faculty. “My dissertation work came out when ChatGPT exploded,” McGee said. “People saw me as a teacher with campus experience, district leadership and administration experience, and I had a doctoral degree. That just wouldn’t have been possible without ACE’s program, and the care and consideration of my teachers.”

ACE President and CEO Geordie Hyland said the college was proud of McGee’s career success.

“Dr. McGee’s commitment to pursuing her doctorate on AI’s role in education is a perfect example of our students’ dedication to learning and mastering the latest advances in their field,” Hyland said. “Students like Dr. McGee are the reason ACE is committed to building programs that teach current, relevant skills, and why we continually refine those programs while relentlessly focusing on keeping our degrees accessible and affordable.”

¹nces.ed.gov/IPEDS/datacenter

²This is an estimated value of the cost for tuition and fees. Amounts may vary depending on number of transfer credits applied to the selected program hours, the pace and satisfactory completion of the selected program, receipt of institutional scholarship and/or grant amounts, or adjustments to tuition or fees as described in the Catalog Right to Modify Tuition section. State sales and use tax will apply where required by law.

³Excludes RN to BSN

About American College of Education

American College of Education (ACE) is an accredited, fully online college specializing in high-quality, affordable programs in education, business, leadership, healthcare and nursing. Headquartered in Indianapolis, ACE offers more than 60 innovative and engaging programs for adult students to pursue a doctorate, specialist, master’s or bachelor’s degree, along with graduate-level certificate programs. In addition to being a leader in online education, ACE is a Certified B Corporation and part of a global movement to use the power of business to solve social and environmental problems.

SOURCE: American College of Education

Related Images

View the original press release on ACCESS Newswire

MELVILLE, NY AND DAVIDSON, NC / ACCESS Newswire / August 27, 2025 / MSC INDUSTRIAL SUPPLY CO. (NYSE:MSM), a leading North American distributor of a broad range of metalworking and maintenance, repair and operations (“MRO”) products and services, today announced the following upcoming investor event:

A real-time audio webcast of MSC’s fireside chat at the Jefferies Industrial Conference can be accessed via the Events and Presentations section of the MSC Industrial Supply Co. Investor Relations website at https://investor.mscdirect.com/events-presentations. A replay of the webcast will be available after the conclusion of the fireside chat and can be accessed on the MSC Industrial Supply Co. Investor Relations website.

# # #

Contact Information

Investors:
Ryan Mills, CFA
Head of Investor Relations
rmills@mscdirect.com

About MSC Industrial Supply Co.

MSC Industrial Supply Co. (NYSE:MSM) is a leading North American distributor of a broad range of metalworking and maintenance, repair and operations (MRO) products and services. We help our customers drive greater productivity, profitability and growth with approximately 2.4 million products, inventory management and other supply chain solutions, and deep expertise from more than 80 years of working with customers across industries. Our experienced team of more than 7,000 associates works with our customers to help drive results for their businesses – from keeping operations running efficiently today to continuously rethinking, retooling and optimizing for a more productive tomorrow. For more information on MSC Industrial, please visit mscdirect.com.

Cautionary Note Regarding Forward-Looking Statements:

Statements in this press release may constitute “forward-looking statements” under the Private Securities Litigation Reform Act of 1995. All statements, other than statements of present or historical fact, that address activities, events or developments that MSC expects, believes or anticipates will or may occur in the future, including statements about results of operations and financial condition, expected future results, expected benefits from our investment and strategic plans and other initiatives, and expected future growth and profitability are forward-looking statements. The words “will,” “may,” “believes,” “anticipates,” “thinks,” “expects,” “estimates,” “plans,” “intends” and similar expressions are intended to identify forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those anticipated by these forward-looking statements. In addition, statements which refer to expectations, projections or other characterizations of future events or circumstances, statements involving a discussion of strategy, plans or intentions, statements about management’s assumptions, projections or predictions of future events or market outlook and any other statement other than a statement of present or historical fact are forward-looking statements. The inclusion of any statement in this press release does not constitute an admission by MSC or any other person that the events or circumstances described in such statement are material. In addition, new risks may emerge from time to time and it is not possible for management to predict such risks or to assess the impact of such risks on our business or financial results. Accordingly, future results may differ materially from historical results or from those discussed or implied by these forward-looking statements. Given these risks and uncertainties, the reader should not place undue reliance on these forward-looking statements. These risks and uncertainties include, but are not limited to, the following: general economic conditions in the markets in which we operate; changing customer and product mixes; volatility in commodity, energy and labor prices, and the impact of prolonged periods of low, high or rapid inflation; competition, including the adoption by competitors of aggressive pricing strategies or sales methods; industry consolidation and other changes in the industrial distribution sector; the applicability of laws and regulations relating to our status as a supplier to the U.S. government and public sector; the credit risk of our customers; the risk of customer cancellation or rescheduling of orders; our ability to accurately forecast customer demands; customer cancellations or rescheduling of orders; interruptions in our ability to make deliveries to customers; supply chain disruptions; our ability to attract and retain sales and customer service personnel; the risk of loss of key suppliers or contractors or key brands; changes to trade policies or trade relationships; risks associated with opening or expanding our customer fulfillment centers; our ability to estimate the cost of healthcare claims incurred under our self-insurance plan; interruption of operations at our headquarters or customer fulfillment centers; products liability due to the nature of the products that we sell; impairments of goodwill and other indefinite-lived intangible assets; the impact of climate change; operating and financial restrictions imposed by the terms of our material debt instruments; our ability to access additional liquidity; the significant influence that our principal shareholders will continue to have over our decisions; our ability to execute on our E-commerce strategies and maintain our digital platforms; costs associated with maintaining our information technology (“IT”) systems and complying with data privacy laws; our ability to remediate a material weakness in our internal control over financial reporting and to maintain effective internal control over financial reporting and our disclosure controls and procedures in the future; disruptions or breaches of our IT systems or violations of data privacy laws, including such disruptions or breaches in connection with our E-commerce channels; risks related to online payment methods and other online transactions; the retention of key management personnel; litigation risk due to the nature of our business; failure to comply with environmental, health, and safety laws and regulations; and our ability to comply with, and the costs associated with, social and environmental responsibility policies. Additional information concerning these and other risks is described under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual and Quarterly Reports on Forms 10-K and 10-Q, respectively, and in the other reports and documents that we file with the United States Securities and Exchange Commission. We expressly disclaim any obligation to update any of these forward-looking statements, except to the extent required by applicable law.

SOURCE: MSC Industrial Direct Co.

View the original press release on ACCESS Newswire

SAN DIEGO, CALIFORNIA / ACCESS Newswire / August 27, 2025 / The YFQ-42A Collaborative Combat Aircraft, designed and developed by General Atomics Aeronautical Systems, Inc. (GA-ASI), is now conducting flight testing in coordination with the U.S. Air Force. This historic achievement continues the company’s rapid creation of new, jet-powered uncrewed platforms chartered by the U.S. Air Force (USAF) to achieve air dominance while being designed for rapid production, in large quantities, at an affordable price.

“What a great moment for the U.S. Air Force and for GA-ASI,” said GA-ASI President David R. Alexander. “It’s been our collaboration that enabled us to build and fly the YFQ-42A in just over a year. It’s an incredible achievement and I salute the Air Force for its vision and I salute our development team for delivering yet another historic first for our company.”

The YFQ-42A is GA-ASI’s newest uncrewed jet, focused on air-to-air semi-autonomous operation and based on the genus-species concept pioneered on the XQ-67A Off-Board Sensing Station (OBSS). Using state-of-the-art, model-based digital engineering, GA-ASI was able to accelerate its schedule while optimizing air dominance capabilities. YFQ-42’s autonomy core has been trained across more than five years of flight testing using GA-ASI’s jet-powered MQ-20 Avenger^®, an aircraft no other company has. The integrated capabilities of a stealthy, air-to-air-focused uncrewed jet, combined with a learned AI autonomy core, provide warfighters with a definitive advantage in the future fight.

The GA-ASI program has focused on creating a high-rate production environment that enables USAF to reach its goal of producing more than 1,000 CCAs on an accelerated timeline. Ground testing for YFQ-42A began in May.

USAF selected GA-ASI in April 2024 to build and fly a fully production-representative Collaborative Combat Aircraft (CCA). In March, USAF designated the aircraft the YFQ-42A, with the “Y” indicating a production-representative aircraft (“Y” will be dropped upon entering production), “F” signifying a fighter aircraft, and “Q” denoting an uncrewed aircraft.

GA-ASI has developed more than two dozen different types of uncrewed aircraft and delivered more than 1,200 units to customers, building more than 100 aircraft per year at its 5 million-square-foot manufacturing facility in Poway, Calif. GA-ASI aircraft have amassed nearly 9 million total flight hours; more than 50 GA-ASI aircraft are aloft around the world every minute of every day.

About GA-ASI

General Atomics Aeronautical Systems, Inc., is the world’s foremost builder of Unmanned Aircraft Systems (UAS). Logging nearly 9 million flight hours, the Predator^® line of UAS has flown for over 30 years and includes MQ-9A Reaper^®, MQ-1C Gray Eagle^®, MQ-20 Avenger^®, and MQ-9B SkyGuardian^®/SeaGuardian^®. The company is dedicated to providing long-endurance, multi-mission solutions that deliver persistent situational awareness and rapid strike.

For more information, visit www.ga-asi.com.

Avenger, EagleEye, Gray Eagle, Lynx, Predator, Reaper, SeaGuardian, and SkyGuardian are trademarks of General Atomics Aeronautical Systems, Inc. registered in the United States and/or other countries.

# # #

SOURCE: General Atomics Aeronautical Systems, Inc.

View the original press release on ACCESS Newswire

CAMBRIDGE, MA / ACCESS Newswire / August 27, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Applications (sBLA) for the 2025-2026 formulas for Spikevax® and mNEXSPIKE®, targeting the LP.8.1 variant of SARS-CoV-2 to help prevent COVID-19.

The updated formula for Spikevax is now approved for individuals 6 months through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19, and all adults 65 years of age and older. mNEXSPIKE, Moderna’s new COVID-19 vaccine, is approved for individuals 12 through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19, and all adults 65 years of age and older. With the U.S. FDA’s decision, Moderna’s updated vaccines are expected to be available in the coming days.

“Protecting people at increased risk of severe outcomes from COVID-19 is imperative to public health as COVID-19 was responsible for up to 4 million outpatient visits and nearly half of a million hospitalizations last year,” said Stéphane Bancel, Chief Executive Officer of Moderna. “We are proud to help ensure Americans will have the latest protection against currently circulating strains this respiratory virus season.”

The updated vaccine composition is based on guidance from the U.S. FDA, which advised that COVID-19 vaccines should be developed with a monovalent JN.1 lineage, with a preference for the LP.8.1 variant.

Moderna’s updated COVID-19 vaccines targeting LP.8.1 have already been granted approval by regulators in Canada, Europe, Japan, Switzerland and other countries. Additional regulatory applications are under review around the world in preparation for the coming season.

About Moderna

Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.

Moderna’s mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.

Spikevax® and mNEXSPIKE®are registered trademarks of Moderna.

What is mNEXSPIKE® (COVID-19 Vaccine, mRNA) AND SPIKEVAX® (COVID-19 Vaccine, mRNA)?

mNEXSPIKE is a vaccine to protect against COVID-19. mNEXSPIKE is for people who are:

• 65 years of age and older, or

• 12 years through 64 years of age at high risk for severe COVID-19.

SPIKEVAX is a vaccine to protect against COVID-19. SPIKEVAX is for people who are:

• 65 years of age and older, or

• 6 months through 64 years of age at high risk for severe COVID-19.

Vaccination with mNEXSPIKE or SPIKEVAX may not protect all people who receive the vaccine.

IMPORTANT SAFETY INFORMATION

You or your child should not get mNEXSPIKE® or SPIKEVAX® if you had a severe allergic reaction after a previous dose of either mNEXSPIKE, SPIKEVAX, any Moderna COVID-19 vaccine, or to any ingredient in these vaccines.

What are the risks of mNEXSPIKE and SPIKEVAX?

There is a very small chance that mNEXSPIKE or SPIKEVAX could cause a severe allergic reaction. A severe allergic reaction would usually occur within a few minutes to 1 hour after getting a dose of mNEXSPIKE or SPIKEVAX. For this reason, your healthcare provider may ask you to stay for a short time at the place where you received your vaccine. Signs of a severe allergic reaction can include:

• Trouble breathing

• Swelling of your face and throat

• A fast heartbeat

• A rash all over your body

• Dizziness and weakness

Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received mRNA COVID-19 vaccines. Myocarditis and pericarditis following mRNA COVID-19 vaccines have occurred most commonly in males 12 years through 24 years of age. You should seek medical attention right away if you or your child has any of the following symptoms after receiving mNEXSPIKE or SPIKEVAX, particularly during the 2 weeks after receiving a dose of the vaccine: chest pain, shortness of breath, feelings of having a fast-beating, fluttering, or pounding heart. Additional symptoms in children may include fainting, irritability, poor feeding, lack of energy, vomiting, pain in the abdomen, or cool, pale skin.

Side effects that have been reported in clinical trials with mNEXSPIKE include:

• Injection site reactions: pain, tenderness and swelling of the lymph nodes in the same arm of the injection, swelling (hardness), and redness.

• General side effects: fatigue, headache, muscle pain, joint pain, chills, nausea, vomiting, and fever

Side effects that have been reported in clinical trials with SPIKEVAX include:

• Injection site reactions: pain, tenderness and swelling of the lymph nodes in the same arm of the injection or in the groin, swelling (hardness), and redness

• General side effects: fatigue, headache, muscle pain, joint pain, chills, nausea and vomiting, fever, rash, irritability/crying, sleepiness, and loss of appetite.

• Fainting and febrile seizures (convulsions during a fever) have also been reported

Tell your vaccination provider about all of your or your child’s medical conditions, including if you or your child:

• have any allergies

• had a severe allergic reaction after receiving a previous dose of any COVID-19 vaccine

• have had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart)

• have a fever

• have a bleeding disorder or are on a blood thinner

• are immunocompromised or are on a medicine that affects your immune system

• are pregnant or plan to become pregnant

• are breastfeeding

• have received any other COVID-19 vaccine

• have ever fainted in association with an injection

These may not be all the possible side effects of mNEXSPIKE and SPIKEVAX. Ask your healthcare provider about any side effects that concern you. You may report side effects to Vaccine Adverse Event Reporting System (VAERS) at 1-800-822-7967 or http://vaers.hhs.gov.

Please click for mNEXSPIKE Full Prescribing Information and Information for Recipients and Caregivers.

Please click for SPIKEVAX Full Prescribing Information and Information for Recipients and Caregivers.

Moderna Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the availability of Moderna’s updated COVID vaccines; the efficacy, safety and tolerability of Moderna’s COVID vaccines; and Moderna’s regulatory applications under review around the world. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading “Risk Factors” in Moderna’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date of this press release.

Moderna Contacts

Media:
Chris Ridley
Head of Global Media Relations
+1 617-800-3651
Chris.Ridley@modernatx.com

Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
Lavina.Talukdar@modernatx.com

SOURCE: Moderna, Inc.

View the original press release on ACCESS Newswire

Founders Dr. Anatoly and Oksana Ripa bring their patient-focused approach and modern dental care to new communities in North Miami-Dade.

MIAMI, FL / ACCESS Newswire / August 27, 2025 / Smile Creators, a boutique dental practice founded by Dr. Anatoly Ripa and Oksana Ripa, has officially expanded with a new clinic in Sunny Isles Beach, and a third location is coming soon to Aventura. With their flagship office in Bay Harbor Islands already serving a diverse Miami clientele, this expansion marks an exciting new chapter for one of the region’s most innovative dental brands. Dr. Ripa, a graduate of Stony Brook University with over 27 years of experience in the field, is known for his personalized approach to aesthetic and restorative dentistry. Fluent in English, Russian, and Ukrainian, he has built long-term relationships with patients across the Bal Harbour and North Miami areas. Alongside him, Oksana Ripa has helped shape Smile Creators into a recognizable name – developing a patient experience that blends hospitality, precision care, and community connection.

The expansion into Sunny Isles Beach reflects a growing demand for access to personalized, high-quality dental care delivered in a calming and modern environment. The upcoming Aventura office, set to open later this year, will extend the practice’s reach even further into North Miami-Dade.

“Our goal has always been to make patients feel confident, cared for, and in control of their health,” said Dr. Anatoly Ripa. “Every new space we create reflects that vision.”

Technology plays a central role in the Smile Creators’ vision. Each location incorporates modern diagnostic tools and workflow systems that support efficient, individualized treatment. The clinical environment – designed under the creative direction of Oksana Ripa – also avoids the traditional feel of a dental office, opting instead for a relaxed, spa-like atmosphere that helps patients feel at ease.

While many patients visit Smile Creators for cosmetic improvements, the clinic maintains a full-scope dental approach that supports oral health at every stage of life. As the practice continues to grow, its core values remain centered on trust, transparency, and a commitment to long-term results.

The Smile Creators team continues to connect with patients both in-person and online. For more information about their services or to schedule a consultation, visit www.smilecreators.com or follow the clinic’s official Instagram at @smilecreators_miami for updates, behind-the-scenes content, and news on the upcoming Aventura launch.

“We’re proud to grow with the communities we serve,” said Oksana Ripa. “For us, expansion isn’t just about more locations – it’s about deeper relationships with the people who walk through our doors.”

In addition to its clinical services, Smile Creators is known for its bold branding – from its signature yellow vehicle seen across Miami to its stylish clinic interiors and strong social media identity. The brand’s connection to the city remains a central part of its success story.

The Sunny Isles Beach location is now open to patients. The Aventura office is currently in development, with a grand opening expected later this year.

Contact:

VUGA Media Group
Miami, FL
Alice Bay
contact@vugamediagroup.com

SOURCE: VUGA Media Group

View the original press release on ACCESS Newswire